BIOMAT Database Logo BIOMAT Database Logo

Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs. 1990

U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Urologische Klinik der Städtischen Kliniken Offenbach, Universität Frankfurt/Main, West-Germany.

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003534 Cyproterone An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. Cyproterone, 1alpha,2 alpha,9 beta,10 alpha-Isomer
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Prostatic cancer: endocrine treatment.
January 1984, The Turkish journal of pediatrics,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
[ENDOCRINE TREATMENT OF PROSTATIC CANCER].
January 1963, Jaarboek van kankeronderzoek en kankerbestrijding in Nederland. Yearbook for cancer research and fight against cancer in the Netherlands,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Endocrine treatment of prostatic cancer.
March 1986, Journal of the Royal Society of Medicine,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Endocrine treatment of prostatic cancer.
June 1983, Urology,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Endocrine treatment of prostatic cancer.
February 1984, Urology,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Endocrine treatment of prostatic cancer.
October 1985, Journal of the Royal Society of Medicine,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Adjuvant endocrine treatment in early prostatic cancer.
January 1991, Acta oncologica (Stockholm, Sweden),
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Simultaneous endocrine management and chemotherapy as initial treatment in M1 prostatic carcinoma.
January 1988, Progress in clinical and biological research,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Aspects on endocrine treatment of prostatic and breast cancer.
January 1957, Acta endocrinologica. Supplementum,
U W Tunn, and A J Goldschmidt, and K Peter, and M Becker
Endocrine factors in the treatment of prostatic cancer.
January 1985, Progress in clinical and biological research,
Copied contents to your clipboard!